amphotericin B

(redirected from Amphotec)
Also found in: Medical, Encyclopedia.

am·pho·ter·i·cin B

An antibiotic, C47H73NO17, derived from strains of the actinomycete Streptomyces nodosus and used to treat systemic fungal infections.


amphotericin B

n anfotericina B
References in periodicals archive ?
3 million charged during 2003 for excess Infergen and Amphotec inventory.
NASDAQ:SEQU) today announced that AMPHOTEC has been approved in Argentina (under the tradename AMPHOCIL(TM)), bringing to 17 the number of countries in which AMPHOTEC has been authorized for sale.
1 million taken for excess Infergen(R) (interferon alfacon-1) and Amphotec inventory.
Gary Noskin of Northwestern Memorial Hospital and Northwestern University Medical School, indicate that AMPHOTEC is safe and effective in the treatment of seriously ill patients with Candida blood stream infection (candidemia).
NASDAQ: SEQU) today announced that AMPHOTEC(TM) has been approved in Italy (under the trade name AMPHOCIL(TM)), bringing to 16 the number of countries in which AMPHOTEC has been authorized for sale.
Under the terms of the agreement, TORREX and its subsidiaries will have exclusive rights to AMPHOTEC for a period of three years, after which SEQUUS has an option to co-market the drug.
Three Rivers also sells Amphotec for treatment of invasive aspergillosis, a dangerous systemic fungal infection, and a generic form of AstraZeneca Plc's (London GBR) breast-cancer treatment Arimidex (anastrozole).
Known by the trade names Abelcet, Ambisome, and Amphotec are lipid formulations of amphotericin B.
Amphotec is indicated for the treatment of invasive aspergillosis, a fungal infection that occurs in immunocompromised patients.
In addition, the new labeling includes information on the safety of AMPHOTEC in pediatric patients.
An increase in total expenses from $10,918,000 in the first quarter of 1996 to $16,088,000 in the first quarter of 1997 was primarily due to increases in research and development spending on expanded clinical trials of DOXIL in solid tumors and increased clinical trial expenses for SPI-077, the third SEQUUS drug to enter clinical trials and the second anticancer drug using the Company's proprietary STEALTH(R) liposome technology, and in increased selling expenses related to DOXIL and AMPHOTEC.
AMPHOTEC and SPI-77 products and for the development and execution of strategies for registration of the SEQUUS pipeline products.